(Q36223219)

English

New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

1 reference

Europe PubMed Central

New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

breast carcinoma

1 reference

based on heuristic

inferred from title

Marcella Mottolese

12

object named as

Marcella Mottolese

0 references

Serena Di Cosimo

object named as

Serena Di Cosimo

9

0 references

object named as

Emilio Bria

2

0 references

Diana Giannarelli

object named as

Diana Giannarelli

3

0 references

Gianluigi Ferretti

4

object named as

Gianluigi Ferretti

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

author name string

Paolo Carlini

1

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

Alessandra Felici

5

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

Paola Papaldo

6

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

Alessandra Fabi

7

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

Cecilia Nisticò

8

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

Enzo Maria Ruggeri

10

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

Michele Milella

11

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

Marcella Mottolese

12

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

Edmondo Terzoli

13

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

Francesco Cognetti

14

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

language of work or name

0 references

publication date

1 October 2005

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

104

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

1335-1342

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21339

7 January 2021

based on heuristic

inferred from DOI database lookup

Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21339

7 January 2021

based on heuristic

inferred from DOI database lookup

Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21339

7 January 2021

based on heuristic

inferred from DOI database lookup

Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21339

7 January 2021

based on heuristic

inferred from DOI database lookup

Aromatase inhibitors in the treatment of advanced breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21339

7 January 2021

based on heuristic

inferred from DOI database lookup

Cross-resistance to different aromatase inhibitors in breast cancer treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21339

7 January 2021

based on heuristic

inferred from DOI database lookup

An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21339

7 January 2021

based on heuristic

inferred from DOI database lookup

Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multiinstitutional trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21339

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21339

7 January 2021

based on heuristic

inferred from DOI database lookup

Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SA

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21339

7 January 2021

based on heuristic

inferred from DOI database lookup

Open comparative trial of formestane versus megestrol acetate in postmenopausal patients with advanced breast cancer previously treated with tamoxifen.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21339

7 January 2021

based on heuristic

inferred from DOI database lookup

Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21339

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21339

7 January 2021

based on heuristic

inferred from DOI database lookup

Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21339

7 January 2021

based on heuristic

inferred from DOI database lookup

The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21339

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival in patients with metastatic breast cancer: analysis of randomized studies comparing oral aromatase inhibitors versus megestrol.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21339

7 January 2021

based on heuristic

inferred from DOI database lookup

Confronting publication bias: a cohort design for meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21339

7 January 2021

based on heuristic

inferred from DOI database lookup

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21339

7 January 2021

based on heuristic

inferred from DOI database lookup

Interpreting Measures of Treatment Effect in Cancer Clinical Trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21339

7 January 2021

based on heuristic

inferred from DOI database lookup

Taxanes with anthracyclines as first-line chemotherapy for metastatic breast carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21339

7 January 2021

based on heuristic

inferred from DOI database lookup

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21339

7 January 2021

based on heuristic

inferred from DOI database lookup

Quality of health care delivered to adults in the United States

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21339

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21339

7 January 2021

based on heuristic

inferred from DOI database lookup

Aromatase inhibitors for chemoprevention

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21339

7 January 2021

based on heuristic

inferred from DOI database lookup

Overall survival is not a realistic end point for clinical trials of new drugs in advanced solid tumors: a critical assessment based on recently reported phase III trials in colorectal and breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21339

7 January 2021

based on heuristic

inferred from DOI database lookup

Economic evaluation of antiaromatase agents in the second-line treatment of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21339

7 January 2021

based on heuristic

inferred from DOI database lookup

Cost-utility analysis of second-line hormonal therapy in advanced breast cancer: a comparison of two aromatase inhibitors to megestrol acetate.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21339

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.21339

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36223219&oldid=1949569793"